We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The overall quality of direct-to-consumer (DTC) advertising has been declining,
according to the head of the FDA's Division of Drug Marketing, Advertising,
and Communications (DDMAC), which last year issued a record number of warning
letters for violations of the agency's ad requirements.
A national coalition led by PhRMA will spend roughly
$30 million through June to develop and promote a program that would help low-income
Americans gain access to the medicines they need.
Pharmexa has entered into an agreement to acquire GemVax AS, a private Norwegian
biotech company focusing on cancer vaccines. The purchase price will be paid
in newly issued Pharmexa shares and by issuance of a convertible debt instrument.
OnSource announced that it executed a definitive agreement to merge (the "Merger
Agreement") with Osmotics Pharma (OPI). OPI is an emerging specialty pharmaceutical
company focused on developing prescription products for the treatment of various
dermatological disorders, antibiotic-resistant strains of bacteria and certain
cancers.
DiObex, a biotechnology company developing therapeutics for the treatment of
metabolic diseases, announced the conclusion of a worldwide exclusive license
agreement with Cortendo Invest AB of Gothenburg, Sweden.
Janus Pharmaceuticals Inc. (Janus) announced the closing of the company's Series
A financing round for a total of over $2 million. Lead investor was Private
Equity Japan Co., Ltd (PEJ). of Tokyo, Japan. Commensurate with this funding,
Mr. Shinji Kimura Managing Director, PEJ, joins the Janus Board of Directors.
Drug companies could face restrictions on advertising medicines under a Federal
Government Budget push to prevent a blowout in Australia's pharmaceutical benefits
scheme (PBS).
Cellegy Pharmaceuticals announced that it has entered into a settlement agreement
with PDI, Inc. resolving the lawsuits that the companies had filed against each
other relating to an exclusive license agreement for Cellegy's Fortigel (testosterone
gel) product candidate in North American markets.
CortDev announced that Botaniex has purchased a 16.5-acre parcel of land in
Zhaoqing High Technology Industry Development Zone, Guangdong Province, China.